Treatment of chronic urticaria with a beta2‐adrenergic stimulant
- 1 January 1977
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 7 (1) , 35-39
- https://doi.org/10.1111/j.1365-2222.1977.tb01422.x
Abstract
Summary: Twenty‐four patients with chronic urticaria resistant to conventional therapy were treated orally with terbutaline, a specific β2 stimulant. This therapy was much more effective than antihistamines. At the dose of 1.25 mg three times a day, there were few side effects. The efficacy was independent of the IgE levels; it seemed greater in idiopathic cases than in cholinergic or pressure induced urticaria.This publication has 7 references indexed in Scilit:
- Cutaneous immediate hypersensitivity in man: Effects of systemically administered adrenergic drugsJournal of Allergy and Clinical Immunology, 1975
- Effect of beta adrenergic stimulation and blockade on immediate hypersensitivity skin test reactionsJournal of Allergy and Clinical Immunology, 1973
- Pharmacologic Control of Allergic Histamine Release in Vitro: Evidence for an Inhibitory Role of 3′,5′-Adenosine Monophosphate in Human LeukocytesThe Journal of Immunology, 1972
- The Relationship of in vitro and in vivo Allergic Histamine Release: Inhibition in Primates by cAMP Active AgentsInternational Archives of Allergy and Immunology, 1972
- Effects of a new stimulator of beta-receptors, terbutaline, on ventilatory capacity, lung resistance, heart rate and blood pressureEuropean Journal of Clinical Pharmacology, 1971
- Two new groups of selective stimulants of adrenergicβ-receptorsCellular and Molecular Life Sciences, 1969